Streamlining Stem Cell Manufacturing
The Factory System Will Help the Stem Cell Industry Standardize, Integrate, and Automate Unit Operations
More Tooth, More Tail in CRISPR Operations
The Most Interesting Thing about CRISPR/Cas9 Is What It Can Accomplish in the Hands of Gifted Researchers
DNA: Past to Present 2017
Celebrate National DNA Day with a Look at Some of the Double-Helix’s Scientific History
Predict Drug Toxicity without Guesswork
Consider Organs-On-Chips, Pathway Simulations, and Transgenic Mice
For full access to this article login to GEN Select now.
Orphan Drug Changes Brewing at the FDA
Initiatives to De-Risk Drug Development Could Include Redesigning Clinical Trial Requirement
- There is an initiative under way to revamp the way FDA approaches orphan drug development that goes above and beyond the 1983 Orphan Drug Act. The 2010 Brownback/Brown amendment was created as a market-based approach to address rare and neglected diseases by incentivizing biotech and pharmaceutical companies to invest ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.